Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Objectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult patients with severe asthma.Materials and methods Thi...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ian Pavord, Robert Chan, Nicola Brown, Peter Howarth, Martyn Gilson, Robert G. Price, Jorge Maspero
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2024-12-01
Series:	Annals of Medicine
Assuntos:	Long-term access program mepolizumab open-label extension safety severe asthma with an eosinophilic phenotype
Acceso en liña:	https://www.tandfonline.com/doi/10.1080/07853890.2024.2417184
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!